OBJECTIVES:  A randomized control trial is ongoing in Trenton, NJ to evaluate the outcomes of using clinical pharmacists to manage chronic diabetics, on Medicaid, with severely uncontrolled HbA1c (>8%). The purpose of this study was to evaluate the impact of pharmacists on the odds of achieving a clinically significant reduction in HbA1c of ≥1% at 6 months, while controlling for potential confounders. METHODS:  A logistic regression model evaluated the impact of the treatment provider and each factor on the odds of HbA1c reduction. Potential confounders for the model were selected from the results of a literature search. A second logistic regression model evaluated the impact of the factors on study dropout. A mathematical correction was applied to the odds ratios to estimate the risk ratio. RESULTS:  A total of 189 patients were randomized and scheduled for follow up appointments. Of the randomized patients, 113 returned for their 6 month follow up appointment. The group treated by the pharmacist demonstrated a 72% increase in the chance of a clinically significant HbA1c reduction (Adjusted OR: 1.72, 95% CI: 1.18-1.92). Treating with a pharmacist also did not produce a statistically significant impact on the odds of study dropout (Adjusted OR: 1.37 95% CI: 0.72-1.54). None of the previously identified confounders had a significant impact on the results. CONCLUSIONS:  In the first 6 months of treatment, utilizing a clinical pharmacist increased the odds of a clinically significant reduction in HbA1c for severely unmanaged diabetics compared to treatment by a physician without increasing the odds of discontinuing treatment. Future research is needed to determine if the results continue past 6 months.